Type your tag names separated by a space and hit enter

Specific Considerations with Liver Disease - Hepatic Function

Specific Considerations with Liver Disease - Hepatic Function is a topic covered in the Clinical Anesthesia Procedures.

To view the entire topic, please or purchase a subscription.

Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drug, procedures and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and MEDLINE Journals. Explore these free sample topics:

Anesthesia Central

-- The first section of this topic is shown below --

Synthesis and Storage

Synthesis and Storage

  1. Proteins. The normal adult liver produces 12 to 15 g of protein per day including the following:
    1. Albumin is manufactured exclusively in the liver and has a half-life of approximately 20 days. It comprises 50% of all circulating plasma proteins and is the most important drug-binding protein, especially for organic acids such as penicillins and barbiturates. Albumin contributes to oncotic pressure and also serves as a carrier protein for bilirubin and hormones.
    2. α1-Acid glycoprotein is an “acute phase reactant” and is responsible for binding basic drugs such as amide local anesthetics, propranolol, and opioids.
    3. Pseudocholinesterase is responsible for the degradation of succinylcholine, mivacurium, and ester-type local anesthetics. In the presence of severely depressed hepatocellular function or a genetically mediated enzyme deficiency, decreased plasma levels may cause profound clinical effects.
    4. All proteinaceous clotting factors are produced in the liver with the exception of factor VIII, which is produced in the vascular endothelium. Synthesis of factors II (prothrombin), VII, IX, and X as well as proteins C, S, and Z are vitamin K dependent; deficiency of vitamin K or disturbances of liver function may lead to deficiencies of clotting factors and excess bleeding. Factor VII has the shortest half-life (4 to 6 hours) and therefore declines at nearly the same rate as protein C (9 hours). Because factor VII is located in the extrinsic pathway, which is assessed by the prothrombin time (PT), this early decline in the factor VII activity prolongs the PT even though other pathways have not yet been affected. Factors II, IX, and X have half-lives of approximately 60, 24, and 36 hours, respectively. Consequently, it takes 4 to 6 days before their activities are at a minimum level, and an antithrombotic effect is achieved that correlates with the INR.
  2. Carbohydrates. The liver is actively involved in the homeostatic regulation of plasma glucose levels (glycogen synthesis and gluconeogenesis). The normal liver can store enough glycogen to provide glucose during a fast of 12 to 24 hours. After that time, glucose is derived by gluconeogenesis from amino acids, glycerol, and lactate.
  3. Lipids. Most of the body's lipoproteins, as well as cholesterol and phospholipids, are formed in the liver.
  4. Heme and bile.
    1. The liver is the primary erythropoietic organ of the fetus and continues to be a major site of hematopoiesis until approximately 2 months of age. In healthy adults, the liver is responsible for 20% of heme production. Abnormalities in heme synthesis can result in porphyria.
    2. The liver forms approximately 800 mL of bile per day. Bile salts are detergents that aid in absorbing, transporting, and excreting lipids. Bile also carries metabolic waste products and drug metabolites to the intestine from the liver. As an emulsifier, bile facilitates fat absorption by the small intestine. Failure to produce or release bile causes jaundice and an inability to absorb fat and fat-soluble vitamins (A, D, E, and K) and can result in steatorrhea, vitamin deficiencies, and coagulopathy.

-- To view the remaining sections of this topic, please or purchase a subscription --


Pino, Richard M., editor. "Specific Considerations With Liver Disease - Hepatic Function." Clinical Anesthesia Procedures, 9th ed., Wolters Kluwer, 2019. Anesthesia Central, anesth.unboundmedicine.com/anesthesia/view/ClinicalAnesthesiaProcedures/728145/all/Specific_Considerations_with_Liver_Disease___Hepatic_Function.
Specific Considerations with Liver Disease - Hepatic Function. In: Pino RM, ed. Clinical Anesthesia Procedures. 9th ed. Wolters Kluwer; 2019. https://anesth.unboundmedicine.com/anesthesia/view/ClinicalAnesthesiaProcedures/728145/all/Specific_Considerations_with_Liver_Disease___Hepatic_Function. Accessed April 19, 2019.
Specific Considerations with Liver Disease - Hepatic Function. (2019). In Pino, R. M. (Ed.), Clinical Anesthesia Procedures. Available from https://anesth.unboundmedicine.com/anesthesia/view/ClinicalAnesthesiaProcedures/728145/all/Specific_Considerations_with_Liver_Disease___Hepatic_Function
Specific Considerations With Liver Disease - Hepatic Function [Internet]. In: Pino RM, editors. Clinical Anesthesia Procedures. Wolters Kluwer; 2019. [cited 2019 April 19]. Available from: https://anesth.unboundmedicine.com/anesthesia/view/ClinicalAnesthesiaProcedures/728145/all/Specific_Considerations_with_Liver_Disease___Hepatic_Function.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Specific Considerations with Liver Disease - Hepatic Function ID - 728145 ED - Pino,Richard M, BT - Clinical Anesthesia Procedures UR - https://anesth.unboundmedicine.com/anesthesia/view/ClinicalAnesthesiaProcedures/728145/all/Specific_Considerations_with_Liver_Disease___Hepatic_Function PB - Wolters Kluwer ET - 9 DB - Anesthesia Central DP - Unbound Medicine ER -